La vendita allo scoperto per Inozyme Pharma Inc Ordinary Shares dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Inozyme Pharma Inc Ordinary Shares. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Inozyme Pharma Inc Ordinary Shares (NASDAQ:INZY) Azioni, Report sulle vendite allo scoperto

INOZYME PHARMA INC

Inozyme Pharma

Inozyme Pharma Inc Ordinary Shares

BTIG analyst Justin Zelin maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Buy and lowers the price target from $64 to $20.

News

Price Target

Analyst Ratings

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

BTIG Maintains Buy on Jasper Therapeutics, Lowers Price Target to $20

WIIM

NDRA

ENDRA Life Sciences shares are trading higher after the company announced it will be granted a US patent titled "Radio Frequency Applicator".

<a href="https://x.com/PatentAlerts4/status/1942312161243718143" title="https://x.com/PatentAlerts4/status/1942312161243718143">https://x.com/PatentAlerts4/status/1942312161243718143</a>

Biotech

General

ENDRA Life Sciences To Be Granted US Patent 'Radio Frequency Applicator.'

NBTX

NANOBIOTIX Announces Announces European Health Authorities Agreed To Formally Reclassify NBTXR3 From A Medical Device To A Drug

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading lower Monday afternoon as markets react to new global trade restrictions announced by the White House. President Donald Trump imposed sweeping 25% tariffs on all goods imported from Japan and South Korea, set to begin Aug. 1.
What To Know: The broad-based duties, which come after a 90-day negotiation period <a href="https://www.benzinga.com/markets/equities/25/07/46281204/wall-street-today-trump-tariffs-japan-south-korea-stocks-drop">expired</a> without a resolution, add to existing tariffs and aim to correct &#8220;unsustainable trade deficits.&#8221;
In official letters, the administration noted the 25% rate was a &#8220;moderate&#8221; measure. The news sent a chill through markets, impacting multinational corporations like Intel that rely on complex global supply chains.
Adding to investor concerns, the administration is <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46282961/super-micro-shares-are-trading-lower-monday-whats-going-on">reportedly preparing</a> to restrict shipments of advanced AI chips to Malaysia and Thailand to prevent the technology from reaching China. 
As a result, the potential for new export licenses and controls on high-performance semiconductors casts a shadow over the entire industry. These dual threats of broad tariffs and specific chip curbs, combined with a looming tariff deadline with the European Union, are weighing heavily on sentiment for major U.S. chipmakers.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga&#8217;s Edge</a> stock rankings, Intel presents a profile that may appeal strongly to value-oriented investors. The stock earns a high value score of 74.75, suggesting it could be trading at a discount relative to its intrinsic worth or industry peers.
However, this strength is contrasted by significant weakness in other key areas. Intel scores poorly on Momentum at 26.55 and receives a very low mark for Growth at 19.18. A ranking for the stock&#8217;s Quality was not available. This data indicates that while Intel may represent a bargain.
INTC Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Intel shares closed Monday down 2.18% to $22. The stock has a 52-week high of $37.16 and a 52-week low of $17.66.
<h2 class="wp-block-heading">How To Buy INTC Stock</h2>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Intel&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Read Also: • <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46282961/super-micro-shares-are-trading-lower-monday-whats-going-on">Super Micro Shares Are Trading Lower Monday: What&#8217;s Going On?</a>
Image: Shutterstock

Global

Movers

Tech

INTC

Intel Shares Tumble On Sweeping Tariffs, AI Chip Curbs

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 44.98% on an annualized basis producing an average annual return of 59.32%. Currently, Vistra has a market capitalization of $65.73 billion. 
Buying $100 In VST: If an investor had bought $100 of VST stock 5 years ago, it would be worth $1,019.47 today based on a price of $193.70 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751919311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Vistra 5 Years Ago Would Be Worth This Much Today

Benchmark analyst David Williams maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and raises the price target from $50 to $55.

IONQ

Benchmark Maintains Buy on IonQ, Raises Price Target to $55

Guidance

MMSI

Merit Medical Sees Prelim. Q2 Revenue $380M-$384M

PBBK

Trading Halt: Halted at 4:10:00 p.m. ET - Trading Halt: Halt News Pending

LAMR

Lamar Advertising Acquires Verde Outdoor's Assets In UPREIT Transaction; Terms Not Disclosed

CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) just made a big move — but the market didn't applaud. Shares of Core Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) plunged nearly 21% on Monday, even as AI cloud provider CoreWeave announced it will acquire the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner in <a href="https://www.benzinga.com/topic/bitcoin-miners">an all-stock deal</a>.
The twist? 
Beth Kindig, CEO and Lead Tech Analyst at I/O Fund, flagged the valuation in a post on X:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">CoreWeave <a href="https://twitter.com/search?q=%24CRWV&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CRWV</a> has agreed to acquire Core Scientific <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a> in an all-stock transaction expected to close in Q4. The exchange ratio implies a $9 billion equity valuation for <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a>, or $20.40 per share value.
&mdash; Beth Kindig (@Beth_Kindig) <a href="https://twitter.com/Beth_Kindig/status/1942202259799957952?ref_src=twsrc%5Etfw">July 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The exchange ratio values Core Scientific at a jaw-dropping $9 billion — or $20.40 per share, a massive premium over its pre-deal price of under $11. That's a valuation level this Bitcoin mining company could have secured only during the heady crypto boom days of 2021. And markets aren't buying it.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280108/coreweave-core-scientific-shares-move-lower-on-9-billion-all-stock-deal">CoreWeave, Core Scientific Shares Move Lower On $9 Billion All-Stock Deal</a>
CoreWeave's stock also dipped 3.9% on the news, despite its own red-hot 293% year-to-date rally. While the company touts the acquisition as a strategic play to vertically integrate and secure cheap, scalable power for its AI infrastructure, investors seem skeptical of marrying high-growth AI with high-volatility crypto mining.
That's a head-turner in today's market, where Bitcoin miners have struggled with compressed margins, regulatory uncertainty, and post-halving revenue pressure. 
Core Scientific is down 12% in the past month and still negative year-to-date — yet CoreWeave's offer implies nearly double the current share price.
CoreWeave's bullish bet hinges on AI's insatiable energy appetite. Owning a Bitcoin mining company such as Core Scientific, which operates massive power-dense data centers, could give CoreWeave better control over energy infrastructure. But the question remains: Can a 2021-style crypto valuation fly in a 2025 market?
For now, the answer from investors is a resounding, "not yet."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46273662/no-plan-b-teslas-musk-premium-is-on-thin-ice">No Plan B &#8211; Tesla&#8217;s Musk Premium Is On Thin Ice</a></li>
</ul>
Photo: PJ McDonnell via Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Markets

$BTC

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

CoreWeave Just Valued Core Scientific Like It's 2021 Again

Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors
Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025

Management

Merit Medical Names Martha Aronson As President And CEO

Contracts

OPXS

Optex Systems Receives $2.8M Purchase Order For Optical Sighting System

Cadence Design Systems, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) shares are lower Monday. They have found resistance around $325 again.
But they may be on the <a href="https://www.benzinga.com/news/25/07/46256825/nvidia-crowdstrike-wolfspeed-cadence-design-systems-and-microsoft-why-these-5-stocks-are-on-investors-radars-today">verge of a breakout</a>. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
In the stock market, certain price levels have more importance than others. As you can see on the chart below, the $325 level is one for Cadence.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="531" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-1024x531.png" alt="" class="wp-image-975421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one.png 1402w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
In early 2024, the stock was trending higher. There weren't enough sell orders to fill all of the buy orders. Those who wished to buy had to continually increase their bid prices to attract sellers into the market. This forced the shares into an uptrend.
In March 2024, the uptrend ended around $325.
There were enough sell orders to fill all of the buy orders. The buyers didn't need to keep pushing the price higher.
But soon after hitting this resistance, the shares reversed and headed lower. When this happened, some people thought their decision to buy was a mistake.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/07/46271577/trumps-big-beautiful-bill-slashes-solar-incentives-cathie-woods-ark-says-nuclear-may-now-be-cheapest-option-oklo-smr-ltbr-and-other-stocks-in-focus">Trump&#8217;s Big Beautiful Bill Slashes Solar Incentives — Cathie Wood&#8217;s Ark Says Nuclear May Now Be Cheapest Option: OKLO, SMR, LTBR And Other Stocks In Focus</a>
They also decided to get out at breakeven if they could eventually do so.
So when Cadence returned to this level in June 2024, these regretful buyers placed sell orders. And there were so many of them that it created resistance again at the same level.
A similar dynamic occurred in December. Remorseful buyers who paid around $325 in June 2024 saw a chance to finally get out at breakeven, and they took it. Their selling put a top on the price once again.
Then, some of the people who had bought shares attempted to exit at breakeven after the price returned to this level in January.  And again, resistance formed.
Now Cadence has returned to this important level once more. The same thing could happen.
However, if the stock can break out above $325, it will indicate that the sellers are no longer present. They have either canceled or finished their orders.
With these sellers out of the way and this large amount of supply taken off of the market, those who wish to buy may start to push the price higher again.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46276421/broadcom-tesla-mag-7-switch-musk-trump-feud">Musk Chaos Could Oust Tesla From Mag 7, Making Way For Broadcom</a></li>
</ul>
Image: Shutterstock

Technicals

CDNS

Stock Of The Day: Breakout Time For Cadence Design?

Horizon, a company offering tailored investment and technology solutions to financial advisors, is introducing two new actively managed ETFs: Horizon Core Bond ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BNDY#BATS">BNDY</a>) and Horizon Flexible Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#BATS">FLXN</a>). This expansion continues the company&#8217;s growth in its fast-growing <a href="https://www.benzinga.com/etfs">ETF family.</a>
Both are structured to assist advisors in producing a steady income while managing risk using options overlays, a strategy that is growing in popularity due to interest rate uncertainty and volatile credit markets.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46277766/tesla-troubles-amplified-by-musks-party-politics-etfs-on-edge">Tesla Troubles Amplified By Musk&#8217;s Party Politics: ETFs On Edge</a>
BNDY focuses on investment-grade fixed-income instruments across a range of maturities like government and corporate bonds, and adds put spread overlays to enhance return potential and buffer volatility. The fund carries an expense ratio of 0.65%.
FLXN, on the other hand, ventures into the high-yield debt space, providing flexibility to adjust holdings based on market conditions, once more employing put spread overlays to cushion downside risk and maximize returns. The expense ratio for this fund is 0.80%.
The launch follows hot on the heels of three other ETF rollouts by Horizon just last week, Horizon Core Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/STOX#BATS">STOX</a>), Horizon Dividend Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DIVN#BATS">DIVN</a>), and Horizon Managed Risk ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/SFTY#BATS">SFTY</a>), bringing the firm&#8217;s ETF lineup to seven.
As fixed-income investing evolves, Horizon&#8217;s latest ETFs represent another step in providing advisers with more nimble and risk-conscious solutions in an increasingly complex market environment.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46281860/elons-america-party-etf-a-what-if-fund-of-musk-linked-stocks-like-tesla-nvidia">Elon&#8217;s America Party ETF: A What-If Fund Of Musk-Linked Stocks Like Tesla, Nvidia</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

BNDY

DIVN

FLXN

SFTY

STOX

Horizon Expands ETF Lineup With 2 Funds For Smarter Bond Income And Volatility Defense

Earnings

EDUC

Educational Development Q1 EPS $(0.13) Up From $(0.15) YoY, Sales $7.100M Down From $9.993M YoY

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will present new data from Week 156 of the Company's Phase 3 PaTHway Trial demonstrating the safety and efficacy of long-term treatment with TransCon&#xAE; PTH (palopegteriparatide) in adults with hypoparathyroidism – including maintenance of serum and urine biochemistries within normal levels and sustained improvement in renal function. Dr. Carlos Bacino will present additional safety and tolerability data from Week 52 of the Company's pivotal ApproaCH Trial of once-weekly TransCon&#xAE; CNP (navepegritide) in children with achondroplasia.

ASND

Ascendis Pharma To Present New Data From Week 156 Of Phase 3 PaTHway Trial Demonstrating Safety And Efficacy Of Long-Term Treatment With TransCon PTH In Adults With Hypoparathyroidism, At ENDO 2025

Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) shares are trading lower on Monday amid possible trade tensions. It was reported that the U.S. is planning to restrict shipments of AI chips to Malaysia and Thailand over China concerns.
According to the&nbsp;<a href="https://www.latimes.com/business/story/2025-07-05/u-s-plans-ai-chip-curbs-on-malaysia-thailand-over-china-concerns?utm_source=chatgpt.com">Los Angeles Times</a>, President Donald Trump's administration is planning new export restrictions that would require U.S. companies to obtain licenses before sending advanced AI chips to Malaysia and Thailand. The goal is to prevent the indirect transfer of sensitive technology to China.
The updated rules, expected to be proposed as soon as August, target countries that have recently seen a rise in chip-related investment and activity.
The measures will likely include temporary exemptions, allowing shipments from U.S. and allied companies to continue for a limited time without a license. Additional exceptions are also being considered to reduce potential supply chain disruptions.
Officials are also expected to scale back a separate rule on AI chip exports that had faced pushback from U.S. allies and tech firms like Nvidia.
Current restrictions on exports to China and over 40 other countries will stay in effect to curb smuggling and closely monitor sensitive markets.
QCOM Price Action: At publication on Monday, Qualcomm shares are trading 2.54% lower at $158.09, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiWjf6OuKuOAxXbAHkGHVuJE9IQFnoECA4QAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Read Now: • <a href="https://www.benzinga.com/news/politics/25/07/46283137/trump-vs-bezos-how-big-beautiful-bill-may-wreck-20k-ev-dream">Trump Vs. Bezos: How &#8216;Big Beautiful Bill&#8217; May Wreck $20K EV Dream</a>
Image via Shutterstock

QCOM

Qualcomm Stock Is Trading Lower Monday: What's Going On?

<a href="https://register.epo.org/application?number=EP20832031">https://register.epo.org/application?number=EP20832031</a>

MBRX

Moleculin Biotech Has Been Granted European Patent Number EP3990041 titled "METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN (FOR THE TREATMENT OF CANCER)

BFST

Business First Bancshares To Acquire Progressive Bancorp, Inc. And Progressive Bank; Expects To Issue ~3,050,490 Shares Of Common Stock To Progressive Shareholders

Press Releases

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVDX, TASK, INZY on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders

Small Cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Comments

Inozyme Pharma Inc Ordinary Shares

Vendite allo scoperto

Inozyme Pharma Inc Ordinary Shares (NASDAQ:INZY) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO